



PRESS RELEASE

**DIAGNOCURE APPOINTS VICE PRESIDENT OF MARKETING AND NATIONAL SALES
Launch of its Previstage™ GCC Colorectal Staging Test on Plan**

QUEBEC CITY, June 26, 2008 – DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, is actively finalizing the imminent launch of its new Previstage™ GCC Colorectal Cancer Staging Test planned for this summer, and appoints Mr. Phillip Wells as Vice President, Marketing and National Sales to drive this launch and commercial growth of the Company.

Phillip Wells holds a Bachelor Degree from the College of Letters and Science, at the University of California, Davis. He has 30 years of experience in marketing in the global healthcare sector, where he held various positions in sales management, marketing, managed care, business development and participated in many successful product launches. Mr. Wells joined DiagnoCure Inc. in 2007 as Senior Director of Reimbursement, where he has been responsible for developing and implementing corporate strategies for gaining reimbursement for the Company's high-value tests. Prior to joining DiagnoCure, Mr. Wells worked at Hoechst Marion Roussel, CV Therapeutics and Prometheus Laboratories where he was responsible for reimbursement policy for both laboratory tests and pharmaceutical products.

After successfully setting the stage for the launch of DiagnoCure's Previstage™ GCC test, Mr. L. Blair Shamel, Sr. Vice President, Corporate Development, has chosen to return to a consulting role. Since joining DiagnoCure in 2003, Mr. Shamel has contributed to the achievement of significant milestones for the Company. Among other contributions, he has been instrumental in negotiating and managing the licensing agreement with Gen-Probe, DiagnoCure's PCA3 development and commercialization partner. Mr. Shamel will continue to contribute to the Company's success as a consultant to the CEO on the diagnostic industry.

"Phillip Wells and his team will now lead the implementation of the marketing and sales strategies with a clear set of goals to bring Previstage™ GCC to the forefront of the management of colorectal cancer", stated John Schafer, President and CEO, "while Blair Shamel will continue to provide DiagnoCure with his strategic consulting expertise."

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA™ PCA3 *in vitro* assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

-30-

Contacts:

Investors

DiagnoCure Inc.

Paule De Blois

Vice President, Corporate Affairs

(418) 527-6100

communications@diagnocure.com

Media

Jean-Pierre Trudel & Associates

Jean-Pierre Trudel

(514) 347-6111

jp.trudel@videotron.ca